(Updates with closing shares in second paragraph.)
Oct. 11 (Bloomberg) -- United Therapeutics Corp.’s shares rose the most in almost a year after the biotechnology company said it will offer $210 million of convertible senior notes to qualified institutional buyers and buy back shares.
The company, seller of treatments for cardiovascular diseases, gained 5 percent to $39.74, the biggest increase since Oct. 28.
The offering of the notes due 2016 may include an option for the initial purchaser to buy as much as an additional $40 million, the Silver Spring, Maryland-based company said in a statement today.
United said it expects to reduce future stock dilution through a convertible note hedge transaction. The company also said it will buy back as much as $212 million in shares as part of a $300 million repurchase program.
--Editors: Bruce Rule, Chris Staiti
To contact the reporter on this story: Anna Edney in Washington at firstname.lastname@example.org.
To contact the editor responsible for this story: Adriel Bettelheim at email@example.com.